In fact, studies in platinum-resistant ovarian cancer have shown that ILKAP, a phosphatase which inactivates ILK, is downregulated by cisplatin treatment, and that silencing ILKAP increases ILK activation and protects cells from cisplatin-induced apoptosis [19]. Here, ILK is linked to ovarian cancer.